• Home
  • About Us
  • Our Science
  • Contact Us
  • More
    • Home
    • About Us
    • Our Science
    • Contact Us
  • Home
  • About Us
  • Our Science
  • Contact Us

Our Science

Sisu's proprietary HI-LiTe platform (HSF1 Interacting-Ligand Technology) facilitates discovery and optimization of small molecules that bind directly to HSF1 to modulate its activity. Direct engagement with the previously "undruggable" target enables Sisu to inhibit or activate HSF1 in specific disease states.


Pipeline


HSF1 is Dysregulated in Disease


    Science Translational Medicine journal article

    Science Translational Medicine publication

    The discovery of the first direct and selective HSF1 binding small molecule by Sisu scientific founders was published in the journal Science Translational Medicine. This highlights selective nuclear HSF1 degradation and tumor regression in Prostate Cancer models.

    https://www.science.org/doi/10.1126/scitranslmed.abb5647


    nature communications publication

    The paper shows that  HSF1 is essential for Leukemia Stem Cell self-renewal and disease progression in AML. The discoveries are highlighted using genetic techniques and Sisu's  HSF1 degrader molecules

    https://doi.org/10.1038/s41467-022-33861-1 

    Copyright © 2022 Sisu Pharma - All Rights Reserved.

    Powered by GoDaddy

    • Home

    This website uses cookies.

    We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

    DeclineAccept